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Pulmonaryfibrosisisaprogressiveandfatalfibroticdiseaseofthelungswithunclearetiology.Recentinsighthassuggestedthatearly
injury/inflammation of alveolar epithelial cells could lead to dysregulation of tissue repair driven by multiple cytokines. Although
dysregulation of interleukin- (IL-) 22 is involved in various pulmonary pathophysiological processes, the role of IL-22 in fibrotic
lung diseases is still unclear and needs to be further addressed. Here we investigated the effect of IL-22 on alveolar epithelial cells
inthebleomycin-(BLM-)inducedpulmonaryfibrosis.BLM-treatedmiceshowedsignificantlydecreasedlevelofIL-22inthelung.
IL-22 produced 𝗾𝗿T cells were also decreased significantly both in the tissues of lungs and spleens. Administration of recombinant
humanIL-22toalveolarepithelialcelllineA549cellsamelioratedepithelialtomesenchymaltransition(EMT)andpartiallyreversed
the impaired cell viability induced by BLM. Furthermore, blockage of IL-22 deteriorated pulmonary fibrosis, with elevated EMT
marker (𝗼-smooth muscle actin (𝗼-SMA)) and overactivated Smad2. Our results indicate that IL-22 may play a protective role in
thedevelopmentofBLM-inducedpulmonaryfibrosisandmaysuggestIL-22asanovelimmunotherapytoolintreatingpulmonary
fibrosis.
1. Introduction
Pulmonary fibrosis can occur as an idiopathic disease or as
a consequence of a variety of connective tissue diseases with
undefined aetiology, including scleroderma, dermatomyosi-
tis/polymyositis,systemiclupuserythematosus,andrheuma-
toid arthritis. Pulmonary fibrosis is characterized by epithe-
lial injury and activation, formation of distinctive subepithe-
lial fibroblast/myofibroblast foci, and excessive extracellular
matrix (ECM) accumulation. Many lines of evidence have
suggestedthatrecurrentinjuriestopulmonaryepithelialcells
and ineffective repair initiate aberrant fibroblastic responses.
Epithelial cells undergo phenotypic changes of epithelial
to mesenchymal transition (EMT), in which the cells lose
their epithelial characteristics and acquire a mesenchymal
phenotype. It is estimated that up to one third of fibroblasts
may be of epithelial origin according to lineage tracing in
murine models of lung fibrosis in vivo [1, 2]. Although this
view has been challenged by Rock et al. [3], it needs further
study not only in mice but also in tissues from patients2 Mediators of Inflammation
with idiopathic pulmonary fibrosis. The key mesenchymal
features of pathological fibrosis are increased numbers of
transdifferentiated fibroblasts, named myofibroblasts. These
cells share features with both fibroblasts and smooth muscle
cells. They overexpress 𝗼-smooth muscle actin (𝗼-SMA) and
areprobablyresponsiblefortheenhancedsynthesisofabnor-
malmatrixobservedinpulmonaryfibrosis[4].Transforming
growth factor (TGF)-𝗽1h a sb e e ns h o w nt op l a yak e yr o l e
in pulmonary fibrosis, not only through its functions to
attract fibroblasts and to stimulate their proliferation, but
also through induction of EMT in alveolar epithelial cells by
activating Smad- or non-Smad signaling pathways [5].
Interleukin-22 (IL-22) is a member of the IL-10 cytokine
f a m i l ya n dp l a y sac r i t i c a lr o l ei ni n fl a m m a t i o n ,i m m u n e
surveillance, and homeostasis in tissues that serve a barrier
function such as skin, respiratory (trachea and lungs) and
gastrointestinal (stomach, small intestines, and colon) tracts
as well as liver, pancreas, and kidney [6]. IL-22 is produced
b ys p e c i a lTa n dn a t u r a lk i l l e r( N K )c e l ls u b s e t s .C e l l so f
nonhematopoietic origin express the IL-22 receptor and
respond to it. IL-22 binds to a membrane receptor complex
composedoftheIL-22R1(IL-22RA1)andIL-10R2(IL-10RB2)
[7], and signals intracellularly mainly through transcription
factor JAK/STAT [8].
Increasing evidence suggested that IL-22 is associated
with respiratory damages. Interestingly, it was also showed
that TGF-𝗽/Smad signaling contributes to BLM-induced
fibrosis by promoting EMT, and recent studies demonstrated
that TGF-𝗽 downregulated the IL-22 producing capacity of
Th17 cells in both human [9, 10] and mouse systems [11]
and inhibited the development of Th22 cells [12]. Similarly,
IL-17A could regulate the properties of IL-22 in the airway
damage and inflammation [13], whereas IL-17A enhanced
BLM-inducedfibrosisinaTGF-𝗽dependentmanner[14].To
date,however,thecrosstalkbetweenIL-22andTGF-𝗽-driven
EMT in pulmonary fibrosis has remained unclear.
In the present study, we investigated the role of IL-22
in EMT in BLM-induced pulmonary fibrosis mouse model
as well as in vitro.W ef o u n dt h a tI L - 2 2i n h i b i t e dB L M -
inducedEMT,suggestingapotentialtherapeuticroleofIL-22
in pulmonary fibrosis.
2. Materials and Methods
2.1. Bleomycin-Induced Pulmonary Fibrosis Mouse Model.
C57BL/6micewerepurchasedfromtheShanghaiLaboratory
Animal Center (Chinese Academy of Sciences). The animal
study was approved by the institutional animal care and
u s ec o m m i t t e eo fH u a s h a nH o s p i t a l ,F u d a nU n i v e r s i t y .A l l
surgery was performed under chloral hydrate anesthesia,
and all efforts were made to minimize suffering. Six- to
eight-week old female C57BL/6 mice were used for the
studies of pulmonary fibrosis. For BLM-induced pulmonary
fibrosis, mice were anaesthetized with 2% chloral hydrate
and administered BLM (Nippon Kayaku) intratracheally at
a dose (uL) of 3.5 units/kg dissolving in total 50ul saline.
C o n t r o lg r o u p sw e r ei n j e c t e dw i t h5 0u Ls a l i n ei nt h es a m e
fashion.Miceweresacrificedatweeks1,3,6,and8afterBLM
injection.Bronchoalveolarlavagefluid(BALF)wascollected.
The left lungs were fixed in 10% formalin, dehydrated, and
embedded in paraffin. The right lungs were frozen in liquid
nitrogenforthesubsequentproteinandmRNAexperiments.
For the in vivo experiment, mice were divided into 4
groups at random: the first and second group were given
BLM as described above and injected intraperitoneally with
1.25𝜇g anti-IL-22 neutralizing monoclonal antibody (Ab)
or isotype Ab (both from PerproTech) suspended in saline
for 2 consecutive weeks, respectively; the third and fourth
group were just given once BLM or saline, respectively,
through intratracheal route, serving as BLM control and
saline control.
2.2. Cell Culture and Stimulation. Human type II alveo-
lar epithelial cells (A549) were a gift from Jiucun Wang’s
lab (obtained from the American Type Culture Collection,
ATCC).A549cellswereharvestedinF-12Kmediumcontain-
ing 10% fetal bovine serum (FBS) with 100U/mL penicillin
and 100ug/mL streptomycin at 37
∘Ci nah u m i d i fi e d5 %
CO2 atmosphere. Confluent cultures of A549 were serum-
starved for 12 hours (h) and then cultured with or without
100mU/mLBLM,subsequentlystimulatedwithrecombinant
human IL-22 (PerproTech) of different concentrations for
48h.Cellviabilitywasmeasuredbycellcountingkit-8(CCK-
8, Dojindo).
2.3. Flow Cytometry for Intracellular Staining. After sterile
phosphate buffered saline (PBS) was infused through the
pulmonary vasculature by right heart puncture to remove
any contaminating peripheral blood mononuclear cells, the
whole lung was digested with collagenase IV (GIBCO) and
DNase I (Sigma) at 37
∘C for 60 minutes (min) on the
shaker. After filtering, erythrocyte lysing, and two washes
with PBS, mononuclear cells from lung homogenates were
incubatedin24-wellplateswithRPMI1640mediumcontain-
ing 10% FBS. For intracellular cytokine staining, total lung
cells were cultured at 10
6 cells/mL in complete RPMI 1640
medium containing cell stimulation cocktail (plus protein
transport inhibitors) (eBioscience, including phorbol 12-
myristate 13-acetate (PMA), ionomycin, and protein trans-
port inhibitors—brefeldin A and monensin) at 37
∘Cf o r
5h. The cells were washed and stained with monoclonal
antibodies directed against CD3 (APC, eBioscience), CD4
(FITC, eBioscience), 𝗾𝗿TCR (FITC, eBioscience), or NKp46
(FITC,eBioscience).Cellswerefixedandpermeabilizedwith
flow cytometry staining buffer (ebioscience) and permeabi-
lization buffer (ebioscience) per manufacturer’s instructions,
followed by staining with IL-22 (PE, eBioscience), or IL-
17A (PE, eBioscience), or isotype controls for 30min at
roomtemperature.Thelymphocytepopulationwasidentified
usingforwardand90
∘ lightscatterpatterns,andfluorescence
intensity was analyzed using a FACS Canto cytometer (BD).
2.4. Real-Time Reverse Transcriptase-Polymerase Chain Reac-
tion (RT-PCR) Assay. Total RNA was isolated from frozen
lungspecimensusingTRIZOLReagent(invitrogen)inaccor-
dance with the manufacturer’s protocols. PrimeScript RTMediators of Inflammation 3
reagent Kit (TaKaRa) was used to reverse-transcribe 1ug
RNA to complementary DNA. Real-time RT-PCR (40 cycles
of denaturation at 95
∘C for 15 seconds and annealing at
60
∘C for 60 seconds) was performed on an ABI Prism
7500 sequence detector (Applied Biosystems) with SYBR
Premix Ex Taq (TaKaRa). GAPDH was used to normalize
t h em R N Al e v e l .Th er e l a t i v ee x p r e s s i o n so fP C Rp r o d u c t s
were determined according to the ΔΔCt method which
compares target gene and GAPDH messenger RNA (mRNA)
expression.
2.5. Western Blot. Total protein concentration was measured
using the BCA protein assay kit (Biyuntian) with bovine
serum albumin (BSA, Sigma-Aldrich) as the standard pro-
tein. Thirty 𝜇go fp r o t e i nw e r el o a d e df o re a c hl a n eo f1 0 %
SDS PAGE gels, followed by electrophoresis, and protein
transferstoPVDFmembranes(Millipore).Afterthetransfer,
membranes were blocked with 5% BSA. Immunoblots were
probed with primary antibody against STAT3 (Cell Signal-
ing Technology), pSTAT3 (Cell Signaling Technology), 𝗼-
SMA(Epitomics),E-cadherin(Bio-world),IL-22(Millipore),
Smad2 (Cell Signaling Technology), pSmad2 (Cell Signal-
ing Technology), or GADPH (Epitomics) at 4
∘Co v e r n i g h t
followed by goat anti-rabbit secondary antibodies (Jackson
ImmunoResearch, 1:10,000 dilution) for 30min at room
temperature.Afterextensivewashing,theimmunoblotswere
visualized by ECL (Pierce) and the band densities for each
phenotype marker were quantified using Image Reader Las-
3000 (Fijifilm) after scanning with a Las-3000 Imaging
Densitometer (Fujifilm).
2.6. Histological Analysis. Paraffin-embedded sections (4𝜇m
in thickness) were stained with hematoxylin and eosin
(H&E)andMasson’strichrome(Sigma-Aldrich)accordingto
the manufacturer’s instructions. For immunohistochemistry
analysis,sectionsweretreatedwith3%hydrogenperoxidefor
10 minutes at room temperature to block endogenous perox-
idase. Subsequently, the sections were incubated with anti-
body against IL-22 (Millipore), 𝗼-SMA (Epitomics), TGF-𝗽
(Santa Cruz), Collagen I (Abcam), or Collagen III (Abcam)
overnight at 37
∘C, and then incubated at 37
∘Cf o r1h o u r
with horseradish peroxidase-conjugated goat anti-rabbit IgG
secondary antibody. Sections were washed 3 times with
PBS between each incubation. After development with 3,3
򸀠-
diaminobenzidine tetrahydrochloride and hydrogen perox-
ide, sections were counterstained with hematoxylin.
2.7. Statistics. Values were expressed as the mean ± SD. An
independenttwo-groupt-testorone-wayanalysisofvariance
(ANOVA) test with LSD’s multiple comparison test was used
to evaluate the significance of differences between groups. P
values less than 0.05 were considered statistically significant.
3. Results
3.1. Pulmonary Fibrosis Induced by Intratracheal Injections of
BLMUndergoesEMT. TodetermineiftheEMTresponsewas
involved in pulmonary fibrosis after BLM administration,
we examined pathological changes and EMT markers (E-
cadherin for epithelial cells and 𝗼-SMA for myofibroblasts)
in the lungs over an 8-week period. In this study, pulmonary
fibrosis in C57BL/6 mice was examined by H&E, Masson’s
trichrome, immunohistochemistry for collagen (Col) I and
Col III staining at the 1st, 3rd, 6th, and 8th week after
BLM or saline treatment, showing that the treatment with
BLM enhanced the collagen deposition in the lung tissues
(Figure 1(a)). Apart from smooth muscle cells of vascu-
lar and bronchiolar walls, 𝗼-SMA was mainly expressed
in myofibroblast (Figure 1(a)). It was shown that 𝗼-SMA
was upregulated, whereas E-cadherin was downregulated in
BLM-treated mice (Figure 1(c)). The increased transcripts of
col1a2 and col3a1 (Figure 1(b)) and protein level of 𝗼-SMA
(Figure 1(c)) showed that the lung fibrosis aggravated after
BLM treatment and peaked around the 3rd week. These data
indicated that BLM-induced lung fibrosis is characterized by
an EMT response.
TGF-𝗽 expression in the lung tissues of BLM-treated
micewashigherthanthatofsaline-treatedmice(Figure 1(a)).
Meanwhile, both phosphorylated (pSmad2) and total Smad2
in the lung tissues of BLM-treated mice were found to
be elevated (Figure 1(c)), and the ratio of pSmad2/Smad2
was significantly increased at the 1st, 3rd, and 6th week
(Figure 1(d)). These results suggested that the TGF-𝗽/Smad2
related EMT process participated in the initiation and devel-
opment of the pulmonary fibrosis.
3.2.DecreasedExpressionofIL-22inBLM-InducedPulmonary
Fibrosis. To determine whether IL-22 was involved in BLM-
induced pulmonary fibrosis, the expression of IL-22 was
evaluated by western blotting (Figure 2(a)), or immuno-
histochemistry (Figure 2(b)). As shown by immunoblots,
total IL-22 production in the lung tissue was significantly
decreased in the BLM-treated mice during 8-week period
(Figure 2(a)), which was in agreement with the histological
findings (Figure 2(b)). In addition, most IL-22-positive cells
were showed to distribute mainly subepithelially, within the
alveoli and vessels. Decrement of IL-22 level, either secreted
or in situ, implicated a potential role of IL-22 in pulmonary
fibrosis.
3.3. Differential Expression of IL-22 and IL-17A by CD4
+T,
TCR𝗾𝗿
+T,NKp46
+ CellsinBLM-InducedPulmonaryFibrosis.
To better understand the origin of IL-22 and IL-17 in BLM-
induced pulmonary fibrosis, the percentages of IL-22 and IL-
1 7p r o d u c e dc e l l sw e r ee x a m i n e di nt h el u n ga n ds p l e e nt i s -
suesofC57BL/6miceafterBLMtreatmentbyflowcytometry.
I nt h el u n gt i s s u e s ,a sc o m p a r e dw i t hs a l i n e - t r e a t e dm i c e ,t h e
percentages of CD4
+IL-22
+,T C R 𝗾𝗿
+IL-22
+,a n dC D 4
+IL-
17
+ cells were significantly reduced in BLM-treated mice,
especially at the 3rd week after the treatment (Figure 3(a)).
Incontrast,BLM-treatedmiceshowedsignificantlyincreased
percentage of TCR𝗾𝗿
+IL-17A
+ T cells at the 1st week in the
lung tissues of BLM-treated mice. In the spleen tissues, the
percentagesofTCR𝗾𝗿
+IL-22
+,N K p 46
+IL-22
+,a n dC D 4
+IL-
17
+ cellswerereduced,butCD4
+IL-22
+ and TCR𝗾𝗿
+IL-17A
+
were increased at the 1st week (Figure 3(b)). In addition,4 Mediators of Inflammation
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Figure 1: Bleomycin-treated mice undergo robust epithelial to mesenchymal transition (EMT). (a) Representative photomicrographs of
lung sections were obtained from mice treated with bleomycin (BLM) or saline (week 3). Sections were stained with hematoxylin and
eosin (H&E), and Masson’s trichrome, as well as by immunohistochemistry for anti-𝗼-smooth muscle actin(𝗼-SMA), anti-collagen I (Col
I), anti-collagen III (Col III), anti-transforming growth factor (TGF)-𝗽 antibody.Bars = 200𝜇m (for H&E and Masson’s trichrome staining),
or 50𝜇m (for immunohistochemistry). (b) Expressions of col1a2 and col3a1 from the lung tissues of BLM-treated mice were measured by
real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis relative to that of saline-treated mice.
#𝑃 < 0.05 (for col1a2);
∗𝑃 < 0.05 (for col3a1). (c) Protein levels of 𝗼-SMA, E-cadherin and GADPH in lung homogenates were determined by western blotting and
analyzed by densitometry compared to GADPH expression. The same amounts of total protein are loaded in each lane. (d) Protein levels
of phosphorylated Smad2 (pSmad2), total Smad2, and GADPH in lung homogenates were determined by western blotting and analyzed by
densitometrycomparedtoGADPHexpression.Thesameamountsoftotalproteinareloadedineachlane.FoldincreaseinpSmad2expression
after normalization to total Smad2 expression is shown.
∗ = 𝑃 < 0.05;
∗∗ = 𝑃 < 0.01. Data presented in (b), (c), and (d) are representative of
results from two independent experiments with five mice in each group. Values are shown as mean ± SEM.
very few IL-17A
+NKp46
+ cells were found in the lung and
spleentissueswithinthesameperiod(datanotshown).These
data indicated that CD4
+ and TCR𝗾𝗿
+ Tc e l l sd i ff e r e n t i a l l y
expressed IL-17A and IL-22 in response to BLM treatment,
suggesting that the subsets of CD4
+IL-22
+,T C R 𝗾𝗿
+IL-22
+,
CD4
+IL-17A
+,a ndT CR𝗾𝗿
+IL-17A
+ Tcellsma yha v edistinct
functions in BLM-induced pulmonary fibrosis.
3.4. Amelioration of BLM-Induced EMT of Alveolar Epithe-
lial Cell A549 by IL-22. To further explore the underlyingMediators of Inflammation 5
BLM
BLM
Saline
Saline
IL-22
0.2
0
0.4
0.6
0.8
1
1.2
1.4
∗∗∗
1  w3  w6  w8  w
1 w 3 w 6 w 8 w 1 w 3 w 6 w 8 w
I
L
-
2
2
(17 kD)
GADPH
(35 kD)
(a)
BLM 3 w Saline 3 w
I
L
-
2
2
(b)
Figure 2: IL-22 is downregulated in lungs from bleomycin-treated
mice. (a) Total protein level of IL-22 in lung homogenates was
determined by western blotting and analyzed by densitometry
comparedtoGADPHexpression.Thesameamountsoftotalprotein
are loaded in each lane. Experiments were performed twice with
similar results, with the same amounts of total protein loaded in
each lane. (b) Representative photomicrographs of lung sections
were obtained from mice treated with BLM or saline (week 3). IL-
22-positive cells were examined by immunohistochemistry. Bars =
50𝜇m.
∗ = 𝑃 < 0.05;
∗∗ = 𝑃 < 0.01. Data presented in (a) are
representative of results from two independent experiments with
five mice in each group. Values are shown as mean ± SEM.
mechanism of IL-22 in BLM-induced pulmonary fibrosis, we
examined IL-22 expression in the lung. Studies have shown
that IL-22R1, a specific receptor, was mainly expressed in
primary alveolar epithelial cell (AEC) of lung tissue [15]. Our
studyshowedthatIL-22R1mRNAwasexpressedinthewhole
murine and human lung tissues, as well as in AEC line A549.
However, IL-22 was not detected in fibroblast cell line HFL1
(Figure 4(a)). The phosphorylation of STAT3 was detected
rapidly after rIL-22 stimulation and reached the peak around
30min (Figure 4(b)), corroborating that the A549 cell line is
responsive to rIL-22.
To test whether IL-22 could influence BLM-induced
pulmonarydamage,BLMwasaddedtoepithelialcellcultures
in either the presence or absence of rIL-22. The A549
epithelial cells after BLM (100nU/mL) treatment for over
48h was shown a significant increase in the expression of
mesenchymal markers-𝗼-SMA, which is suggestive of the
process of EMT. Furthermore, we demonstrated that the
addition of exogenous rIL-22 to the culture medium signifi-
cantlydownregulatedBLM-induced𝗼-SMAinepithelialcells
in a dose-dependent manner (Figure 4(c)). Furthermore,
analysis of cell viability by CCK-8 revealed that treatment
of IL-22 at indicated concentrations could partially reverse
the decreased cell viability induced by BLM (Figure 4(d)).
Collectively, these results suggest that IL-22 may protect
AECsfromdevelopmenttowardsEMTandimpairedviability
induced by BLM.
3.5. Deterioration of BLM-Induced Pulmonary Fibrosis by
Anti-IL-22 Neutralizing Antibody. S i n c es u b s t i t u t er h I L - 2 2
could ameliorate BLM-induced EMT, we suspect that block-
age of IL-22 may deteriorate BLM-induced lung fibrosis. To
further address our hypothesis, we administrated anti-IL-22
neutralizing antibody (Ab) intraperitoneally daily for 2 con-
secutive weeks starting from the day of BLM treatment. The
levels of IL-22 both in the serum and BALF were decreased
significantly confirmed by ELISA (data not shown). Treat-
m e n to fa n t i - I L - 2 2A bl e dt oe v e nh i g h e rl y m p h o c y t e si n
BALF than isotype antibody treated control, suggesting IL-
22 may have potential to inhibit the assembly of lymphocytes
in BALF induced by BLM (Figure 5(a)). Strikingly, the BLM-
induced pulmonary fibrosis was much worse after the IL-
22 neutralizing Ab treatment as compared with the isotype
Ab-control, shown by H&E and Masson’s trichrome-stained
lung sections (Figure 5(b)). Immunohistochemical stains of
the lung tissues showed an increased expression of Col I and
Col III, which was in line with the elevated relative transcript
levels of col1a2 and col3a1 measured by real-time RT-PCR
(Figures 5(b) and 5(c)).
EMT markers were also examined after anti-IL-22 neu-
tralizing Ab treatment.
𝗼-SMA-expressing myofibroblasts were shown to be
increased and mainly distributed peritracheally and perivas-
cularly. Of note, 𝗼-SMA was also expressed in some epithe-
lial cells, especially in anti-IL-22 neutralizing Ab treated
mice. Expression of TGF-𝗽 examined by immunohisto-
chemistry was higher than that in the isotype Ab-treated
lungs(Figure 5(b)).Conversely,neutralizingIL-22antibodies
enhanced BLM-induced transcription levels of 𝗼-sma and
mmp2 (Figure 5(c)). The increased expression of transcript
for tgf-𝗽 by real-time RT-PCR was shown in the anti-IL-22
neutralizingAb-treatedlungtissuesascomparedwithisotype
Ab-treated mice, but this did not reach statistical significance
(Figure 5(d)). The ratio of pSmad2/total Smad2 was signifi-
cantly elevated by 147.9% in the anti-IL-22 neutralizing Ab-
treated lungs relative to that of isotype Ab-treated control
(Figure 5(d)).Takentogether,thesedataprovidetheevidence
that IL-22 regulates the process of BLM-induced EMT and
pulmonary fibrosis, likely via TGF-𝗽/Smad2 signaling path-
way.
4. Discussion
Having emerged as an important cytokine in innate immu-
nity, regeneration, and protection from damage, IL-22 plays
either a protective or a pathogenic role in different condi-
tions. In the present study, we investigated a BLM-induced
pulmonary fibrosis model for 8 weeks and found a pro-
gressive process of EMT, aberrant reepithelization, ultimate6 Mediators of Inflammation
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Figure 3: Infiltration of IL-22/IL-17 produced cells in the lungs and spleens induced by intratracheal injections of bleomycin (BLM).
Representative flow cytometry pictures of CD4
+IL-22
+ and TCR𝗾𝗿
+IL-22
+ cell from the lung and spleen tissues at the 3rd week were shown
in Figure 1(a). And the percentages of CD4
+IL-22
+,T C R 𝗾𝗿
+IL-22
+,N K p 4 6
+IL-22
+,C D 4
+IL-17
+,a n dT C R 𝗾𝗿
+IL-17
+ c e l l si nt h el u n g s( b )
and spleens (c) were counted by flow cytometry analysis at the indicated week (w). Data presented in (b) and (c) are from two independent
experiments with 8∼10 mice in each group. Values are the mean and SEM.
∗𝑃 < 0.05.
deposition of ECM, and destruction of lung architectures,
accompanied by significantly decreased production of IL-22.
ThoughIL-22hasbeenreportedtohavebothpathogenicand
protective properties depending on the nature of the affected
t i s s u ea n dt h el o c a lc y t o k i n em i l i e u ,h e r ew es h o w e dt h a t
anti-IL-22 antibody treatment exacerbated the lung fibrosis
in vivo, indicating a potential protective role of IL-22 in the
development of lung fibrosis. Also IL-22 inhibited the over-
expression of 𝗼-SMA and partially reversed the cell viability
of epithelial cells induced by BLM in vitro,w h i c hf u r t h e r
confirmed the in vivo results. In addition, in order to identify
which IL-22 expressed cell subsets play a role in this case, weMediators of Inflammation 7
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examined the CD4
+IL-22
+,T C R 𝗾𝗿
+IL-22
+,N K p 4 6
+IL-22
+
cell both in the lung and spleen at the indicated time points
byflowcytometry.AndwefoundthatIL-22mainlyproduced
𝗾𝗿T cells were decreased significantly both in the lung and
spleen at the 3rd week, indicating TCR𝗾𝗿
+IL-22
+ cell may
participate in the regulation of pulmonary fibrosis. Taken
together, our studies identified IL-22 as a critical regulator
of pulmonary fibrosis after BLM administration, implicating
the potential utility of IL-22 in the treatment of pulmonary
fibrosis.
Simonian et al. showed that IL-22-secreting 𝗾𝗿Tc e l l s
could protect lung fibrosis by inhibiting recruitment of8 Mediators of Inflammation
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𝗼𝗽 T cells in a mouse model of Bacillus subtilis-induced
hypersensitivitypneumonitisfibrosis[16].Ontheotherhand,
Sonnenberg’s group reported a pathogenic role of IL-22 in
a model of high-dose-BLM-induced acute lung damage and
inflammation. IL-22 has been shown to act synergistically
with IL-17A to promote acute pathological airway inflam-
mation. Conversely, anti-IL-22 Ab was found to exacerbate
BLM-induced airway inflammation in il17a
−/− mice, indi-
cating that IL-22 is tissue protective in the absence of IL-17A.
Moreover, IL-17A regulated IL-22-mediated protection from
BLM-induced airway epithelial cell apoptosis [13]. BraunMediators of Inflammation 9
et al. reported ColV-pretreated animals led to a significant
r e d u c t i o ni nl u n gi n fl a m m a t i o n ,w h i c hw a sa s s o c i a t e dw i t h
a significant decrease in the relative expression of interleukin
(IL)-6, IL-17, and IL-22 in cells present in BAL fluid at 7 and
14 days after BLM instillation. However, the evidence of lung
fibrosis needs to be supplied, and more functional details of
IL-22 in the development of BLM induced lung fibrosis need
further study [17].
Evidence has shown that activated T cells, NK cells,
N K Tc e l l s ,l y m p h o i dt i s s u ei n d u c e r( L T i )c e l l s ,a n dL T i -
like cells express IL-22, whereas resting or activated B cells,
monocytes, monocyte-derived macrophages and immature
a n dm a t u r eD C sw e r en o ta b l et op r o d u c et h i sc y t o k i n e
[18–25]. Interestingly, we found that the percentages of IL-
22 expressing CD3
+CD4
−CD8
− oligoclonal 𝗾𝗿Tc e l l sw e r e
significantly decreased both in the lung and spleen at the
3rd week, consistent with the decreased levels of IL-22 as
confirmed by western blotting and immunohistochemistry.
In the previously reported mouse model of hypersensitivity
pneumonitis,theauthorsfoundthatIL-22-secreting𝗾𝗿Tcells
could protect from lung fibrosis by diminishing recruitment
of CD4
+Tc e l l st ot h el u n g .V 𝗾6/V𝗿1
+ 𝗾𝗿 Tc e l l sa r et h ep r e -
dominant cell type in the lung producing IL-22 in response
to chronic B. subtilis exposure. Hence, 𝗾𝗿Tc e l l sm a yp l a yt h e
critical role as an inhibitor of pulmonary fibrosis via IL-22
[16].
CD3
−NKp46
+ c e l l sh a v eb e e nr e p o r t e dt ob ep r e s e n t
in the bone marrow, spleen, thymus, liver, intestines, and
lymph nodes and play a role in epithelial cell homeostasis
a sad i s t i n c ts u b s e to fN Kc e l l ,s o - c a l l e d“ N K 2 2 ”c e l l sw h i c h
express IL-22 and ROR𝗾Tb u tl a c kt h ec a p a c i t yt op e r f o r m
“classical” NK cell functions such as cytotoxicity and IFN-
𝗾 production [26]. Our data show that IL-22 expressed
CD3
−NKp46
+ cells also existed in lung, with no significant
differencebetweenBLM-inducedlungfibrosisandthesaline-
treated control. IL-17A expressed NKp46
+ cells were found
neither in the spleen nor in the lung. Thus, our findings are
unique in that NK22 cells are also present in the lung, but the
function of NK22 cell needs further research.
IL-22 has been shown to bind to the IL-22R1/IL-10R2
receptor complex to mediate its biological effects. Impor-
tantly,onlytheexpressionofIL-22R1determinescellularsen-
sitivity towards IL-22 due to the ubiquitous expression of IL-
10R2. We demonstrated that IL-22R1 mRNA was expressed
in both human and murine lung tissue, and IL-22R1 was
expressed only in alveolar epithelial cell line A549 but not in
fibroblast cell line HFL1. This result was in agreement with
the previous study that IL-22 was found only in primary
epithelial cells, but not in alveolar macrophages, monocytes,
or neutrophils [15]. Taken together, these data suggest that
alveolar epithelial cells may act as the exclusive target cell of
IL-22 in the lung. In the next step, we will test the expression
ofIL-22R1intheprimarycellsfromthelungtissuesofhuman
andmouse.OurdatathatIL-22inducedthephosphorylation
of STAT3 after treating A549 immediately with rhIL-22,
reaching the peak around 30 minutes further corroborates
this notion.
TGF-𝗽 was treated as a central pathogenic contributor in
tissue fibrosis. Interestingly, evidence has shown that TGF-
𝗽 c o u l di n h i b i tt h eI L - 2 2p r o d u c i n gc a p a c i t yo fTh 1 7c e l l s
both in the human [9, 10]a n dt h em o u s e[ 11]. Additionally,
the development of Th22 cells is downregulated by TGF-𝗽
[12]. So whether IL-22 could perform the feedback regula-
tion on TGF-𝗽 signaling deserved our intense investigation.
Stimulation of TGF-𝗽 on the receptor complex led to the
activation of Smad2 and Smad3 through direct C-terminal
phosphorylation by T𝗽RI. TGF-𝗽/Smad signaling pathway
could mediate fibrosis through the mechanism of EMT.
Studies have indicated that lung epithelial cell-specific loss of
𝗼3integrinexpressionreducedEMTandprotectedfromlung
fibrosis, apparently by inhibiting tyrosine phosphorylation
of 𝗽-catenin and formation of 𝗽-catenin/Smad2 complex,
and it was confirmed in IPF patients [27]. These findings
demonstratedSmad2wasrequiredfortheepithelialintegrin-
dependentprofibroticcrosstalkbetween𝗽-cateninandSmad
signaling during process of EMT [27]. Additional line of
evidencehasshownthatTGF-𝗽couldinduceA549cellswith
an alveolar epithelial type II cell phenotype to undergo EMT,
dependent of phosphorylation of Smad2 [5]. Recently Rock
e ta l .p r o p o s e dt h a tt y p eI Ia l v e o l a rc e l l s( A E C 2 )a r en o ta
major source of myofibroblasts through EMT [3], which is
an innovative idea about the origin of myofibroblast. But a
lot of humans, mice, and cell data still support EMT as an
important event in the development of lung fibrosis [28–
33]. So this point still needs further investigation. In our
studies, the phosphorylation of Smad2 was found elevated
in the lungs of BLM-treated mice. Administration of anti-
IL-22 neutralizing antibody resulted in further increase of
phosphorylated Smad2, as well as the increment level of
TGF-𝗽. We think that IL-22 may play a protective role
in pulmonary fibrosis through inactivating TGF-𝗽/Smad
signaling. However, we could not exclude other pathway
altered by IL-22 in downregulation of EMT. For example,
non-Smadsignaling,suchasErkMAPkinases,RhoGTPases,
and the PI3 kinase/Akt pathway, could also mediate TGF-𝗽
induced EMT, and more detailed functional characterization
are warranted.
Pulmonary fibrosis in human can be a fatal disorder
characterized by progressive disease that leads to respiratory
failure. Our studies revealed a close association between IL-
22 and pulmonary fibrosis. Furthermore, we demonstrated
thatneutralizingIL-22couldleadtotheexacerbationofEMT
process and an excessive deposition of ultimate collagen.
In turn, administration of rIL-22 could inhibit EMT of
epithelial cells. Thus, the ability of IL-22 to regulate BLM-
induced pulmonary fibrosis both in vivo and in vitro raises
the possibility that IL-22 may act as a potential target to
treat diseases characterized by chronic lung inflammation
and fibrosis.
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